Article of the Week

Oxidized CaMKII promotes asthma through the activation of mast cells

Oxidized CaMKII promotes asthma through the activation of mast cells

Posted by  | Article of the Week

ARTICLE: Oxidized CaMKII promotes asthma through the activation of mast cells AUTHORS: Jingjing Qu, Danh C. Do, Yufeng Zhou, Elizabeth Luczak, Wayne Mitzner, Mark E. Anderson and Peisong Gao JOURNAL: JCI Insight. 2017 Jan 12;2(1):e90139. doi: 10.1172/jci.insight.90139. Abstract Oxidation of calmodulin-dependent protein kinase II (ox-CaMKII) by ROS has been associated with asthma. However, the contribution of ox-CaMKII to(...)

Read More

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis

Posted by  | Article of the Week

ARTICLE: Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. AUTHORS: Emily A Kendall, Anthony T Fojo, David W Dowdy JOURNAL: Lancet Respir Med. 2016 Dec 16. pii: S2213-2600(16)30423-4. doi: 10.1016/S2213-2600(16)30423-4. [Epub ahead of print] Abstract BACKGROUND: In May, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper(...)

Read More

Dementia and Alzheimer’s Disease among Older Kidney Transplant Recipients

Dementia and Alzheimer’s Disease among Older Kidney Transplant Recipients

Posted by  | Article of the Week

ARTICLE: Dementia and Alzheimer's Disease among Older Kidney Transplant Recipients AUTHORS: Mara A. McAdams-DeMarco, Sunjae Bae, Nadia Chu, Alden L. Gross, Charles H. Brown IV, Esther Oh, Paul Rosenberg, Karin J. Neufeld, Ravi Varadhan, Marilyn Albert, Jeremy Walston and Dorry L. Segev JOURNAL: J Am Soc Nephrol. 2016 Dec 15. pii: ASN.2016080816. [Epub ahead of print] Abstract Older patients with ESRD who receive a kidney transplant (KT) may develop(...)

Read More

Stop Randomizing All Cardiac Arrests

Stop Randomizing All Cardiac Arrests

Posted by  | Article of the Week

ARTICLE: Stop Randomizing All Cardiac Arrests AUTHORS: Myron L. Weisfeldt JOURNAL: Circulation. 2016 Dec 20;134(25):2035-2036. The field of resuscitation science is characterized nearly uniformly by failed clinical trials: be it sodium bicarbonate, epinephrine at low or high dose, vasopressin, continuous or interrupted chest compressions, temperature management, antiarrhythmic drug use, or devices to augment perfusion, none has(...)

Read More

Navigating Ethical Tensions in High-Value Care Education

Navigating Ethical Tensions in High-Value Care Education

Posted by  | Article of the Week

ARTICLE: Navigating Ethical Tensions in High-Value Care Education AUTHORS: Matthew DeCamp and Kevin R. Riggs JOURNAL: JAMA. 2016 Dec 6;316(21):2189-2190. doi: 10.1001/jama.2016.17488. Enthusiasm for high-value care is increasing throughout health care, including in the education of medical students, residents, and fellows.1 Until recently, there were few examples of educational programs that equipped future physicians with the tools required to practice high-value(...)

Read More

Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy

Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy

Posted by  | Article of the Week

ARTICLE: Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy AUTHORS: John W. McEvoy, Seth S. Martin, Zeina A. Dardari, Michael D. Miedema, Veit Sandfort, Joseph Yeboah, Matthew J. Budoff, David C. Goff,Bruce M. Psaty, Wendy S. Post, Khurram Nasir, Roger S. Blumenthal, Michael J. Blaha JOURNAL: Circulation. 2016 Nov 23. pii: CIRCULATIONAHA.116.025471. [Epub ahead of print] Abstract BACKGROUND: There is interest in using atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP)(...)

Read More

Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes

Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes

Posted by  | Article of the Week

ARTICLE: Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes AUTHORS: Peter Abadir, Alka Jain, Laura Powell, Qian-Li Xue, Jing Tian, Robert G. Hamilton, David Bennett, Thomas Finucane, Jeremy D. Walston, Neal S. Fedarko JOURNAL: Circulation. 2016 Nov 30. pii: CIRCULATIONAHA.116.022385. [Epub ahead of print] Abstract BACKGROUND: -Agonistic angiotensin II type I receptor autoantibodies (AT1RaAbs) have not been associated with functional measures or risk for adverse health outcomes. AT1RaAbs(...)

Read More

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Posted by  | Article of the Week

ARTICLE: Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia AUTHORS: Zhaohui Gu, Michelle Churchman, Kathryn Roberts, Yongjin Li, Yu Liu, Richard C. Harvey, Kelly McCastlain, Shalini C. Reshmi, Debbie Payne-Turner, Ilaria Iacobucci, Ying Shao, I-Ming Chen, Marcus Valentine, Deqing Pei, Karen L. Mungall, Andrew J. Mungall, Yussanne Ma, Richard Moore, Marco Marra, Eileen Stonerock, Julie M. Gastier-Foster, Meenakshi Devidas, Yunfeng Dai, Brent Wood, Michael Borowitz, Eric E. Larsen, Kelly Maloney, Leonard A. Mattano Jr, Anne Angiolillo, Wanda L. Salzer, Michael J. Burke, Francesca(...)

Read More

Glucagon-like peptide-1 receptor agonists and risk of breast cancer

Glucagon-like peptide-1 receptor agonists and risk of breast cancer

Posted by  | Article of the Week

ARTICLE: Glucagon-like peptide-1 receptor agonists and risk of breast cancer. AUTHORS: Shari D Bolen and Nisa M Maruthur JOURNAL: BMJ. 2016 Oct 20;355:i5519. doi: 10.1136/bmj.i5519. Although many providers and some patients know about the potential risks of pancreatic or thyroid cancer with use of glucagon-like peptide-1 (GLP-1) receptor agonists,1 2 3 risk of breast cancer has also recently arisen(...)

Read More